3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Myeloid, Acute
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Pinealoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Diseases
1
Neuroendocrine Tumors
1
Myeloproliferative Disorders
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Kidney Neoplasms
1
Hodgkin Disease
1
Fallopian Tube Neoplasms
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Interventions
Cyclophosphamide
82
fludarabine phosphate
68
Mycophenolic Acid
59
Whole-Body Irradiation
52
Peripheral Blood Stem Cell Transplantation
51
Tacrolimus
49
Melphalan
44
Etoposide
42
Busulfan
39
fludarabine
36
Rituximab
36
Filgrastim
36
Granulocyte Colony-Stimulating Factor
35
Brentuximab Vedotin
33
Cyclosporine
32
Doxorubicin
28
Methotrexate
27
Antilymphocyte Serum
27
Radiotherapy
24
Dacarbazine
19
Vinblastine
18
Nivolumab
18
Cytarabine
18
Prednisone
16
Carmustine
16
thymoglobulin
15
Stem Cell Transplantation
15
Sirolimus
15
Alemtuzumab
14
Vincristine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hodgkin Disease
×
entinostat
×
Clear all
NCT00866333
2019-10-22
ENGAGE-501
Syndax Pharmaceuticals
Phase 2
Terminated
49 enrolled
12 charts